James A. Neidhart

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 1.7K citations

Medicine, Hematology, Oncology +14

Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale

Patricia J. Hollen, Richard J. Gralla, Mark G. Kris et al. · Cancer · 1994 · 244 citations · Full text

Pharmacy, Oncology, Cancer Symptom Management +16

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

Glen J. Weiss, Joseph Chao, Jeffrey D. Neidhart et al. · Investigational New Drugs · 2013 · 220 citations · Full text

Pharmacy, Oncology, Pharmacology +14

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 156 citations · Full text

Medicine, Hematology, Oncology +14

Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.

Rasim Gucalp, Paul S. Ritch, P H Wiernik et al. · Journal of Clinical Oncology · 1992 · 151 citations

Medicine, Pharmacology, Pharmacotherapy +10